Anti-Androgenic Therapies Targeting the Luminal Androgen Receptor of a Typical Triple-Negative Breast Cancer

• Published in: Cancers 2022-12, Vol.15 (1), p.233
• Main Authors: Khadela, Avinash, Chavda, Vivek P, Soni, Shruti, Megha, Kaivalya, Pandya, Aanshi J, Vora, Lalitkumar
• Format: Article
• Language: English
• Subjects: Androgen receptors; Androgens; Antiandrogens; Biomarkers; Breast cancer; Cancer therapies; Cell cycle; Chemotherapy; Classification; Clinical trials; Complications and side effects; Dosage and administration; Epidermal growth factor; Estrogens; Gene expression; Histology; Kinases; Lymph nodes; Mesenchyme; Metabolism; Mutation; Proteins; Review; Stem cells; Steroids; Tumor necrosis factor-TNF; Tumors; Vascular endothelial growth factor
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers15010233

Triple-negative tumors are progressively delineating their existence over the extended spectrum of breast cancers, marked by intricate molecular heterogeneity, a low overall survival rate, and an unexplored therapeutic approach. Although the basal subtype transcends the group and contributes approximately 80% to triple-negative breast cancer (TNBC) cases, the exceptionally appearing mesenchymal and luminal androgen receptor (LAR) subtypes portray an unfathomable clinical course. LAR with a distinct generic profile frequently metastasizes to regional lymph nodes and bones. This subtype is minimally affected by chemotherapy and shows the lowest pathologic complete response. The androgen receptor is the only sex steroid receptor that plays a cardinal role in the progression of breast cancers and is typically overexpressed in LAR. The partial AR antagonist bicalutamide and the next-generation AR inhibitor enzalutamide are being assessed in standard protocols for the mitigation of TNBC. There arises an inevitable need to probe into the strategies that could neutralize these androgen receptors and alleviate the trajectory of concerning cancer. This paper thus focuses on reviewing literature that provides insights into the anti-androgenic elements against LAR typical TNBC that could pave the way for clinical advancements in this dynamic sphere of oncology.